Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

the treatment of cancer.  VAL-083 has been assessed in multiple clinical studies sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer.

DelMar is currently conducting a Phase I/II clinical trial with VAL-083 as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  In April 2012, DelMar presented data at the American Association of Cancer Research (AACR website:  http://www.aacr.org) annual meeting demonstrating that VAL-083 maintains activity in tumors resistant to the current front-line GBM therapy, Temodar®.  In November 2012, DelMar presented interim data from the ongoing GBM clinical trial at the Annual Meeting of the Society for NeuroOncology (SNO website:  http://www.soc-neuro-onc.org) demonstrating that VAL-083 can shrink or halt the growth of tumors in brain cancer patients who have failed other approved treatments.  Currently, there is no approved therapy for these patients. 

In addition to the Company's clinical development activities in the United States, DelMar has obtained exclusive commercial rights to VAL-083 in China.  In October 2012, DelMar announced a collaboration agreement with the only manufacturer presently licensed by the Chinese State Food and Drug Administration (SFDA) to produce VAL-083 for the China market.  This agreement provides DelMar with exclusive commercial right
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... Proove Biosciences ... bi-annual Pain Management Medical Advisory Board meeting in Palm Springs, California. At the ... Development team to discuss new clinical practice and research ideas. The Board also ...
(Date:7/6/2015)... -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women,s ... Executive Officer, and Scott Durbin , Viveve,s Chief Financial ... , , , DATE:    , , , ...     , , , 12:15 PM EDT , ...   ,    ...
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... July 3, 2015  Pomerantz LLP announces that a ... Inc. ("Puma" or the "Company")(NYSE: PBYI ) and ... United States District Court, Central District of ... behalf of a class consisting of all persons or ... and May 13, 2015 inclusive (the "Class Period").  This ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4
... Bridge Between North Carolina And ChinaRESEARCH TRIANGLE PARK, ... Institutes for Health Sciences has signed an agreement ... Medical City Institute for International Drug Development. Building ... research, business development, and education, the Institute will ...
... System Can Also Be Used For Mini-Open And Open ... SNN ; LSE: SN) Endoscopy Division today ... to treat injuries to the biceps tendon in the ... the first that enables surgeons to re-attach the biceps ...
... and ALL Highlighted at the 14th Congress of ... Breast Cancer to Be Presented at the American ... 20 Micromet, Inc. (Nasdaq: MITI ... for the treatment of cancer, inflammation and autoimmune ...
Cached Biology Technology:The Hamner Institutes Announce Partnership With China Medical City 2The Hamner Institutes Announce Partnership With China Medical City 3Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair 2Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... PROVIDENCE, R.I. [Brown University] -- Material chemists and engineers ... shells, containers or structures that could be used as ... electronic devices. There have been some successes with ... of possible starting points that could yield the ideal ...
... and Technology (NIST) spent 75 days on the job ... dwelling" of the release, distribution and fate of particles ... DNA molecule. Particles ranging in size from 100 nanometers ... and electric stoves, hair dryers, power tools and candles ...
... WASHINGTON -- A new report released today by the ... produced with less damage to the environment. It is ... marine fish compare to unlabeled options in the marketplace. ... to help seafood buyers sort through competing sustainability claims ...
Cached Biology News:Researchers find best routes to self-assembling 3-D shapes 2Researchers find best routes to self-assembling 3-D shapes 3Elusive ultrafine indoor air contaminants yield to NIST analysis 2New study puts eco-labels to the test 2
CMRL Medium-1066 (1X) liquid...
... 11(R)-HETE is biosynthesized by the 11(R)-LOs ... and the fresh water hydra, H. ... relates to oocyte maturation and tentacle ... is also produced when aspirin-treated recombinant ...
... The PhosphatidylEthanolamine-Binding Protein (PEBP) does ... serine protease inhibitors. PEBP is ... spleen, testis, ovary, muscle, and stomach. ... involved in is exerting inhibitory activity ...
... 500 Power Supply is designed ... offers extensive programming capabilities including ... methods for you to set ... simple intuitive PowerEase interface is ...
Biology Products: